{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:59:55Z","timestamp":1787021995940,"version":"build-2736575974"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Centers for Disease Control, Taiwan","award":["MOHW103-CDC-C-114-000405"],"award-info":[{"award-number":["MOHW103-CDC-C-114-000405"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0171596","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T14:24:14Z","timestamp":1487687054000},"page":"e0171596","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Multicenter study of skin rashes and hepatotoxicity in antiretroviral-na\u00efve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan"],"prefix":"10.1371","volume":"12","author":[{"given":"Pei-Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Eng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chien","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Song","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hsing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chieh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"ref1","article-title":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents","year":"2015"},{"key":"ref2","article-title":"European Guidelines for treatment of HIV-infected adults in Europe","year":"2015"},{"key":"ref3","article-title":"British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015","year":"2015"},{"key":"ref4","article-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: what's new","year":"2015"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cit246","article-title":"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study","volume":"57","author":"AF Luetkemeyer","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAD.0b013e328340fdf8","article-title":"Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis","volume":"25","author":"E Bendavid","year":"2011","journal-title":"Aids"},{"issue":"9417","key":"ref7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"F van Leth","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00126334-200404150-00007","article-title":"Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study","volume":"35","author":"R Manfredi","year":"2004","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"e88497","DOI":"10.1371\/journal.pone.0088497","article-title":"Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy","volume":"9","author":"KY Lee","year":"2014","journal-title":"PloS one"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","article-title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis","volume":"27","author":"Z Shubber","year":"2013","journal-title":"Aids"},{"issue":"2","key":"ref11","first-page":"67","article-title":"Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review","volume":"12","author":"B Gazzard","year":"2010","journal-title":"AIDS reviews"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1086\/367898","article-title":"A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1","volume":"187","author":"D Moodley","year":"2003","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00002018-200932020-00007","article-title":"Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project","volume":"32","author":"JM McKoy","year":"2009","journal-title":"Drug safety"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors","volume":"59","author":"A Rivero","year":"2007","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"I Sanne","year":"2005","journal-title":"The Journal of infectious diseases"},{"issue":"15","key":"ref16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/00002030-200310170-00007","article-title":"Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996\u20132001","volume":"17","author":"WP Law","year":"2003","journal-title":"Aids"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"e94854","DOI":"10.1371\/journal.pone.0094854","article-title":"Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?","volume":"9","author":"FS Sarfo","year":"2014","journal-title":"PloS one"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"MS Sulkowski","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine","volume":"4","author":"L Martin-Carbonero","year":"2003","journal-title":"HIV clinical trials"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"E Martinez","year":"2003","journal-title":"The New England journal of medicine"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy","volume":"15","author":"E Martinez","year":"2001","journal-title":"Aids"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"e9183","DOI":"10.1371\/journal.pone.0009183","article-title":"Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa","volume":"5","author":"KM Chu","year":"2010","journal-title":"PloS one"},{"issue":"Suppl 2","key":"ref23","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1086\/381450","article-title":"Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors","volume":"38","author":"DT Dieterich","year":"2004","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"Suppl 1","key":"ref24","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00126334-200309011-00005","article-title":"A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients","volume":"34","author":"JO Stern","year":"2003","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1258\/09564620360719840","article-title":"Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients","volume":"14","author":"J Ena","year":"2003","journal-title":"International journal of STD & AIDS"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00126334-200108150-00002","article-title":"Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy","volume":"27","author":"M Nunez","year":"2001","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/hiv.12071","article-title":"Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load <\/ = 100 000 copies\/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials","volume":"15","author":"JM Molina","year":"2014","journal-title":"HIV medicine"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials","volume":"27","author":"CJ Cohen","year":"2013","journal-title":"Aids"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/jac\/dks130","article-title":"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials","volume":"67","author":"M Nelson","year":"2012","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ajg.2008.159","article-title":"Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination","volume":"104","author":"HY Sun","year":"2009","journal-title":"The American journal of gastroenterology"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"e90194","DOI":"10.1371\/journal.pone.0090194","article-title":"Seroprevalence of hepatitis B virus among adults at high risk for HIV transmission two decades after implementation of nationwide hepatitis B virus vaccination program in Taiwan","volume":"9","author":"HY Sun","year":"2014","journal-title":"PloS one"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"e0140574","DOI":"10.1371\/journal.pone.0140574","article-title":"Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study","volume":"10","author":"YC Lee","year":"2015","journal-title":"PloS one"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijid.2014.08.012","article-title":"Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan","volume":"29","author":"YT Tseng","year":"2014","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jac\/dkv284","article-title":"Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan","volume":"71","author":"CC Lai","year":"2016","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jac\/dkr601","article-title":"Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan","volume":"67","author":"CC Lai","year":"2012","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"ref36","article-title":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events","year":"2014"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1038\/emi.2013.83","article-title":"Slow immunological progression in HIV-1 CRF07_BC-infected injecting drug users","volume":"2","author":"PH Lin","year":"2013","journal-title":"Emerging microbes & infections"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1468-1293.2006.00396.x","article-title":"Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash","volume":"7","author":"W Manosuthi","year":"2006","journal-title":"HIV medicine"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1468-1293.2010.00873.x","article-title":"Nevirapine-associated hepatotoxicity was not predicted by CD4 count >\/ = 250 cells\/muL among women in Zambia, Thailand and Kenya","volume":"11","author":"PJ Peters","year":"2010","journal-title":"HIV medicine"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"S Chantarangsu","year":"2009","journal-title":"Pharmacogenetics and genomics"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6405-6-22","article-title":"HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients","volume":"6","author":"S Likanonsakul","year":"2009","journal-title":"AIDS research and therapy"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","article-title":"Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy","volume":"186","author":"FW Wit","year":"2002","journal-title":"The Journal of infectious diseases"},{"issue":"7","key":"ref43","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/QAD.0b013e32835e0752","article-title":"Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis","volume":"27","author":"N Ford","year":"2013","journal-title":"Aids"},{"issue":"17","key":"ref44","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/00002030-199817000-00010","article-title":"Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?","volume":"12","author":"M John","year":"1998","journal-title":"Aids"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1086\/315143","article-title":"Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy","volume":"180","author":"MV Ragni","year":"1999","journal-title":"The Journal of infectious diseases"},{"issue":"9","key":"ref46","doi-asserted-by":"crossref","first-page":"e106141","DOI":"10.1371\/journal.pone.0106141","article-title":"Multicenter study of trimethoprim\/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia","volume":"9","author":"JJ Yang","year":"2014","journal-title":"PloS one"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"ofw009","DOI":"10.1093\/ofid\/ofw009","article-title":"Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study","volume":"3","author":"H Kovari","year":"2016","journal-title":"Open forum infectious diseases"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0171596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:55:11Z","timestamp":1540338911000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0171596"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0171596","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}